Purpose
To create the next generation of gene editing tools that deliver durability and cost-efficient manufacturability of genetic medicines.
About
Gene Weaver is harnessing the power of natural gene editing repair processes to deliver high precision and efficient gene modification.
Mission
To comprehensively understand and control the mechanism of action of programmable genetic cargo insertion machines.
To drive uptake of this natural gene insertion approach across a significant portion of the gene editing/therapy technology market.
Vision
To make genetic medicines available to the widest possible patient population.
Gene Weaver is a Cambridge-based biology technology leader driving the development of next generation gene modification tools. Founded in mid-2023 by Recombinase Polymerase Amplification (RPA) technology inventor Dr Niall Armes, the interdisciplinary team of protein engineers, cell biologist, bioinformaticians, is employing a unique enzymatic system with the potential to transform gene editing.
By employing a unique naturally derived enzymatic system, the Gene Weaver Technology Platform will allow large edits to be made in a controlled way, efficiently.
The cost of manufacturing will also be reduced by enhancing the durability of the gene insertion step. Together, these will make the genetic medicine revolution available to a broader patient population, including those in low- and middle-income countries (LMIC).
